Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.

European journal of haematology - 1 Dec 2020

Johansson Patricia, Klein-Hitpass Ludger, Röth Alexander, Möllmann Michael, Reinhardt Hans Christian, Dührsen Ulrich, Dürig Jan

Abstract excerpt

OBJECTIVE: Infusional alemtuzumab followed by consolidating allogeneic hematopoietic stem cell transplantation in eligible patients is considered a standard of care in T-cell prolymphocytic leukemia (T-PLL). Antibody selection against CD52 has been associated with the development of CD52-negative leukemic T cells at time of relapse. Clinical implications and molecular mechanisms underlying this phenotypic switch...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Immunophenotyping

Share to Membrane Proteins

Share to Mutation

Share to Phenotype

Share to T-Lymphocytes

Source

Identifiers

PMID: 32875608
DOI: 10.1111/ejh.13511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.PMID 32875608Read ↗

High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor-/CD52- T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.Semantic proximity Read ↗

Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment.Semantic proximity Read ↗

A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT.Semantic proximity Read ↗

Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency.Semantic proximity Read ↗

Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH.Semantic proximity Read ↗

X inactivation and somatic cell selection rescue female mice carrying a <i>Piga</i> -null mutationSemantic proximity Read ↗

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapySemantic proximity Read ↗

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.Semantic proximity Read ↗

Paroxysmal nocturnal hemoglobinuria caused by CN-LOH of constitutional PIGB mutation and 70-kbp microdeletion on 15q.Semantic proximity Read ↗

Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.Semantic proximity Read ↗

Expansion of donor-derived hematopoietic stem cells with PIGA mutation associated with late graft failure after allogeneic stem cell transplantation.Semantic proximity Read ↗

Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.